Proton Pump Inhibitors are a type of medications that work by reducing the amount of acid produced in the stomach. They are commonly used for treating gastric and duodenal ulcers, gastroesophageal reflux disease and other conditions caused by excessive stomach acid. These medications provide effective relief from symptoms such as heartburn and acid regurgitation. With rising geriatric population worldwide, the incidence of acid-related disorders has increased at an alarming rate. According to estimates, over 60 million Americans experience acid reflux symptoms every year.
The global Proton Pump Inhibitors Market is estimated to be valued at US$ 3.8 Mn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The rising geriatric population presents a massive market opportunity for Proton Pump Inhibitors. Older adults are more prone to acid-related disorders due to a decline in digestive functions with age. According to the United Nations, the population aged 60 years and above is expected to double from 12% to 22% between 2015 and 2050. As per a Harvard study, over 60% of Americans aged 65 and above experience symptoms of acid reflux at least once a month. With the aging demographic trend worldwide, the need for drugs that provide relief from excessive stomach acid is projected to increase substantially. This represents a huge opportunity for manufacturers to develop effective and safe PPI drugs targeted towards the elderly population.
Porter's Analysis
Threat of new entrants: Low as this is a mature market dominated by large pharmaceutical players who have patent protection on popular drugs. New players require large investment in R&D.
Bargaining power of buyers: Moderate to high as major buyers include large pharmacy chains and hospitals that can negotiate on price and demand new product launches.
Bargaining power of suppliers: Moderate as key raw materials and active pharmaceutical ingredients have alternatives however changing suppliers requires regulatory approvals.
Threat of new substitutes: Moderate threat from newly launched drugs or those in pipeline targeting acid reflux disease however PPIs remain gold standard.
Competitive rivalry: High among leading players to gain market share and expand indications through continuous innovations.
SWOT Analysis
Strengths: Established brands, clinical effectiveness at relieving symptoms, widespread insurance coverage and strong distribution networks.
Weaknesses: Concerns around long term safety risks such as bone fractures and magnesium deficiency, rising generic competition eroding prices of major drugs.
Opportunities: Expanding indications to new disease areas, emerging markets witnessing rise in acid reflux cases, combinations with other drugs.
Threats: Safety alerts reducing prescription rates, disruptive technologies offering non-drug alternatives, unfavorable drug price control policies.
Key Takeaways
The Global Proton Pump Inhibitors Market Share is expected to witness high growth over the forecast period driven by increasing instances of acid reflux disease and preference for pharmaceutical treatment options. The global Proton Pump Inhibitors Market is estimated to be valued at US$ 3.8 Mn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2031.
Regional analysis indicates North America currently dominates due to well-established healthcare systems and higher diagnosis rates while Asia Pacific is poised to be the fastest growing market supported by economic growth, rising medical expenditures and shift towards western lifestyle in many countries.
Key players operating in the Proton Pump Inhibitors market are Horizon Therapeutics plc, Ammonett Pharma LLC, Medison Pharma Ltd., Modern Dietetics Inc., Synageva BioPharma Corp., Medison Pharma Ltd., Swedish Orphan Biovitrum AB (Sobi), Entera Health, Inc., Dipharma Francis S.r.l., Ucyclyd Pharma, Inc. Horizon Therapeutics holds a leading share through its popular brand Dexilant while Ammonett and Medison Pharma enjoy strong positions in the generic drug space.
For more insights, Read- https://www.trendingwebwire.com/proton-pump-inhibitors-market-growth-demand-and-overview/
Get more insights on this topic: https://captionssky.com/bottled-water-industry-in-united-states-an-ever-growing-segment/
Comments
0 comment